A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

PURPOSE: Histone deacetylase (HDAC) inhibition has been shown to induce pharmacologic “BRCAness” in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC and PARP inhibition in cancer types that are insensitive to single-agent PARP...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Louise, Truong, Sarah, Zhai, Beibei, Joshi, Jay, Ghaidi, Fariba, Lizardo, Michael M., Shyp, Taras, Kung, Sonia H.Y., Rezakhanlou, Alireza M., Oo, Htoo Zarni, Adomat, Hans, Le Bihan, Stephane, Collins, Colin, Bacha, Jeffrey, Brown, Dennis, Langlands, John, Shen, Wang, Lallous, Nada, Sorensen, Poul H., Daugaard, Mads
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472104/
https://www.ncbi.nlm.nih.gov/pubmed/37279093
http://dx.doi.org/10.1158/1078-0432.CCR-22-3897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472104/
https://www.ncbi.nlm.nih.gov/pubmed/37279093
http://dx.doi.org/10.1158/1078-0432.CCR-22-3897

Ejemplares similares